Streetbeat News

Regulatory

NSTD

Shares of Northern Star Investment Corp have been halted due to pending news. The nature of the news is not yet disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 8:07 pm

WKHS

Workhorse Group Inc. (WKHS) has received approval from the Internal Revenue Service (IRS) for a commercial clean vehicle credit. This could potentially boost the company's sales as it makes their electric vehicles more affordable to customers.

Portfolio Pulse from Bill Haddad

September 12, 2023 | 8:06 pm

BAYRY

CVS

GSK

JNJ

KVUE

PG

RAD

RBGLY

WBA

An FDA panel has unanimously voted against the effectiveness of phenylephrine, a drug ingredient used in several leading decongestants. If the FDA follows the panel's recommendations, companies like Johnson & Johnson, Kenvue Inc, Bayer AG, GSK Plc's Haleon Plc, Procter & Gamble Company, Reckitt Benckiser Group and others may have to pull their oral medications containing phenylephrine from store shelves. This could also impact pharmacy retailers like CVS Health Inc, Walgreens Boots Alliance Inc, and Rite Aid Corp.

Portfolio Pulse from Vandana Singh

September 12, 2023 | 8:06 pm

MOR

MorphoSys AG has received Fast Track designation from the U.S. FDA for its investigational drug tulmimetostat, intended for the treatment of advanced, recurrent or metastatic endometrial cancer. This is the third clinical program by MorphoSys to receive such designation, aimed at expediting the development and review of medicines for serious conditions.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 8:04 pm

RCKT

Rocket Pharmaceuticals has reached an agreement with the FDA on the design of a pivotal Phase 2 trial for RP-A501 in Danon Disease. The company anticipates filing the Clinical Trial Application (CTA)/Investigational Medicinal Product Dossier (IMPD) for RP-A501 in the third quarter of this year to initiate EU study activities. Rocket has also secured an ICD-10 code from CMS for LAMP2 deficiency in Danon Disease.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 8:02 pm

AAPL

Apple Inc.'s shares are trading lower following a report suggesting Huawei is increasing its Mate 60 series smartphone shipment target by 20%. This comes after China's ban on the use of Apple devices for official use and the introduction of Huawei's Mate 60 and Mate 60 Pro smartphones. Apple also showcased the iPhone 15 at its Wonderlust event.

Portfolio Pulse from Ryan Gustafson

September 12, 2023 | 7:50 pm

COIN

Coinbase Global Inc (NASDAQ: COIN) is investing in Truflation, a provider of verifiable economic data, as part of its support for Web3 and Blockchain technologies. Coinbase is also advocating for standardized crypto regulations at the upcoming G20 summit.

Portfolio Pulse from Khyathi Dalal

September 12, 2023 | 7:40 pm

CURLF

The New York State Office of Cannabis Management (OCM) is expanding its licensing program for recreational marijuana, starting October 4. Businesses can apply for multiple cannabis-related licenses via the New York Business Express platform. The OCM has provisions for Social and Economic Equity applicants, who receive 50% off application and licensing fees. However, the entry of industry giants like Curaleaf Holdings Inc (OTCQX:CURLF) could threaten smaller businesses. The OCM board has also approved a cannabis research license application.

Portfolio Pulse from Joana Scopel

September 12, 2023 | 7:36 pm

SPY

Commerce Secretary Gina Raimondo is expected to meet with U.S. business CEOs on Thursday, according to sources. The specifics of the meeting are not disclosed.

Portfolio Pulse from Benzinga Newsdesk

September 12, 2023 | 7:33 pm

TEVA

Teva Pharmaceutical Industries Ltd (NYSE:TEVA), the primary producer of Adderall, faced shortages last year due to a lack of factory workers. The shortage led customers to seek other options, depleting supplies from competitor companies. Despite calls from the U.S. government to increase production, major players, including Teva, have announced no plans to enhance their output. The U.S. Drug Enforcement Administration imposes limits on ADHD medication production, which some producers argue prevent them from fully addressing demand.

Portfolio Pulse from Vandana Singh

September 12, 2023 | 6:53 pm